Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients.
Zheng X, Fang M, Fan Y, Sun Y, Sun M, Yang A, Zhang B, Liu Q, Liu H, Zhou X, Huang T, Qin J, Wang Z, Qin M, Shen Z, Yao S, Yang J, Wang Y, Gao M.
Zheng X, et al. Among authors: wang z, wang y.
Endocr Relat Cancer. 2024 Feb 14;31(4):e230134. doi: 10.1530/ERC-23-0134. Print 2024 Apr 1.
Endocr Relat Cancer. 2024.
PMID: 38261313